Objective response at week 25 was 54% with pimicotinib versus 3% with placebo, supporting robust antitumor activity in unresectable TGCT. Patient-reported endpoints showed meaningful improvements in ...

Paul, a liver cancer survivor, and his wife Emma share their journey of recovery, caregiving and finding balance in life ...

Rosemary Carrera discusses her breast cancer journey, mastectomy and the personal decision to remove her implants at the ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...

Earlier-line bispecific therapy leverages lower disease refractoriness to drive deeper, more durable responses than typically ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...

Success in cancer care increasingly includes survivorship outcomes, emphasizing durable function and symptom control for patients cured and those with prolonged metastatic disease. Variable survival ...

I was participating in a Drumming Clinical Study, which I really enjoyed. And I was so disappointed that I was unable to ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and ...

A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...

Broad endorsement for insurance-covered blood-based CRC screening (92%) suggests payer policy could materially influence ...